BioPorto aktie (BIOPOR) | Pressmeddelande

BioPorto Sponsors Conferences on Pediatric Critical Care with New NGAL Scientific Data Presented

GlobeNewswire • 26 Sep 10:13

US News & World Report Webinar “New Frontiers in Kidney Care” features NGAL biomarker

GlobeNewswire • 11 Sep 08:26

Grant of Warrants

GlobeNewswire • 01 Sep 18:15

ProNephro AKI™ (NGAL), early detection test for Acute Kidney Injury, now commercially available to US Labs through BioPorto’s collaboration with Roche Diagnostics.

ProNephro AKI™ (NGAL), early detection test for Acute Kidney Injury, now commercially available to US Labs through BioPorto’s collaboration ...

GlobeNewswire • 28 Aug 12:06

BioPorto Interim Result for the Second Quarter of 2025 - Continued progress with full execution of strategic objectives and strong NGAL sales growth.

BioPorto Interim Result for the Second Quarter of 2025 - Continued progress with full execution of strategic objectives and strong NGAL sale...

GlobeNewswire • 15 Aug 07:57

BioPorto A/S to host an investor webcast on the results for the first half of 2025

GlobeNewswire • 29 Jul 15:28

BioPorto attends the Association for Diagnostics & Laboratory Medicine meeting, where NGAL and Acute Kidney Injury will be a key focus among participants.

BioPorto attends the Association for Diagnostics & Laboratory Medicine meeting, where NGAL and Acute Kidney Injury will be a key focus among...

GlobeNewswire • 28 Jul 16:52

BioPorto attends the Association for Diagnostics & Laboratory Medicine meeting, where NGAL and Acute Kidney Injury will be a key focus among participants.

BioPorto attends the Association for Diagnostics & Laboratory Medicine meeting, where NGAL and Acute Kidney Injury will be a key focus among...

GlobeNewswire • 28 Jul 16:40

Initiation of commercialization of ProNephro AKI (NGAL) for diagnostic use in the US

GlobeNewswire • 27 Jun 09:20

Grant of Warrants

GlobeNewswire • 12 Jun 19:56

BioPorto A/S Announces the Appointment of a New CEO as Part of its Succession Planning Strategy

GlobeNewswire • 10 Jun 16:20

Continued progress on key strategic milestones in Q1 2025. Total revenue in line with expectations and guidance for 2025 maintained.

Continued progress on key strategic milestones in Q1 2025.

GlobeNewswire • 08 May 08:19

Grant of Warrants

GlobeNewswire • 28 Apr 18:28

BioPorto A/S to host first quarter 2025 earnings webcast for investors

GlobeNewswire • 28 Apr 16:41

BioPorto announces completion of an oversubscribed directed offering of 25 million new shares raising DKK 33.5 million

BioPorto announces completion of an oversubscribed directed offering of 25 million new shares raising DKK 33.

GlobeNewswire • 25 Apr 14:07

Managers’ transactions

GlobeNewswire • 25 Apr 13:55

BioPorto A/S raises DKK 33.5 million in new capital round - Change of number of shares and votes

GlobeNewswire • 25 Apr 13:45

Correction: Private placement of 25,000,000 new shares fully subscribed – gross proceeds of DKK 33.5 million, to BioPorto A/S

Correction: Private placement of 25,000,000 new shares fully subscribed – gross proceeds of DKK 33.

GlobeNewswire • 15 Apr 08:31

Private placement of 25,000,000 new shares fully subscribed – gross proceeds of DKK 33.5 million, to BioPorto A/S

Private placement of 25,000,000 new shares fully subscribed – gross proceeds of DKK 33.

GlobeNewswire • 15 Apr 08:15

BioPorto A/S initiates a private placement of up to 25,000,000 new shares at market price. The Board of Directors has received advance indications for the full offering which is expected to raise proceeds of DKK 33.5 million.

BioPorto A/S initiates a private placement of up to 25,000,000 new shares at market price.

GlobeNewswire • 14 Apr 16:55

BioPorto A/S announces Jens Due Olsen as a Board of Directors candidate intending to appoint Jens Due Olsen as Chair, along with updates on other candidates

BioPorto A/S announces Jens Due Olsen as a Board of Directors candidate intending to appoint Jens Due Olsen as Chair, along with updates on ...

GlobeNewswire • 04 Mar 21:28

Strengthening of Investor Focus – BioPorto enters Market Maker Agreement with Danske Bank & appoints New Head of Investor Relations

GlobeNewswire • 27 Feb 18:05

BioPorto A/S appoints new interim Chairman of the Board

GlobeNewswire • 29 Jan 18:16

BioPorto announces the publication of urinary NGAL reference ranges in healthy adult and pediatric individuals

GlobeNewswire • 23 Jan 13:23

Preliminary Financial Figures for the 2024 Fiscal Year

GlobeNewswire • 06 Jan 18:16

BioPorto commences process to appoint new Chair of the Board of Directors

GlobeNewswire • 16 Dec 2024 18:53

BioPorto Announces Interim Results and Business Update for the Third Quarter and Nine Months of Fiscal 2024

GlobeNewswire • 14 Nov 2024 08:50

BioPorto A/S to Host Third Quarter 2024 Earnings Webcast

GlobeNewswire • 12 Nov 2024 09:57

BioPorto Sponsors Exhibits to Showcase Launch of ProNephro AKI in the U.S. and Ongoing Marketing of The NGAL Test to Clinicians at Major Healthcare Conferences

BioPorto Sponsors Exhibits to Showcase Launch of ProNephro AKI in the U.

GlobeNewswire • 08 Nov 2024 17:03

Grant of Warrants

GlobeNewswire • 04 Nov 2024 18:44

First Patient In - BioPorto Initiates Patient Enrollment for US Study of ProNephro AKI (NGAL)™ for Adult Use at Massachusetts General Hospital

First Patient In - BioPorto Initiates Patient Enrollment for US Study of ProNephro AKI (NGAL)™ for Adult Use at Massachusetts General Hospit...

GlobeNewswire • 29 Oct 2024 08:56

BioPorto Enters Global Distribution Partnership with Beckman Coulter for Acute Kidney Injury NGAL Tests

GlobeNewswire • 28 Oct 2024 16:26

BioPorto Presenting FDA-cleared ProNephro AKI (NGAL) at ASN Kidney Week 2024 Conference

GlobeNewswire • 23 Oct 2024 17:15

BioPorto is proud to have Nine of the top-ten best US Children’s hospitals as customers of NGAL

GlobeNewswire • 22 Oct 2024 08:04

BioPorto A/S Announces Changes to the US Commercial Organization

GlobeNewswire • 21 Oct 2024 17:15

BioPorto Announces Appointment of National Principal Investigator and Selection of CRO for Upcoming USA ICU Adult AKI Clinical Study

GlobeNewswire • 10 Oct 2024 16:17

Første 6 måneder af 2024: Fortsat stærk vækst i salget af NGAL-tests i USA og fokuseret eksekvering af alle elementer i BioPortos strategi

GlobeNewswire • 15 Aug 2024 08:58

BioPorto Announces Interim Results and Business Update for the Second Quarter and Six Months of Fiscal 2024

GlobeNewswire • 15 Aug 2024 08:37

BioPorto A/S to Host Second Quarter 2024 Earnings Webcast & Investor Meeting

GlobeNewswire • 07 Aug 2024 13:04

BioPorto Announces NIH-Funded Study to Explore the Ability of Renal Biomarkers in Predicting Severe AKI, Advancing Beyond NLP-based AI Algorithms

BioPorto Announces NIH-Funded Study to Explore the Ability of Renal Biomarkers in Predicting Severe AKI, Advancing Beyond NLP-based AI Algor...

GlobeNewswire • 30 Jul 2024 17:15

BioPorto to Debut FDA Approved ProNephro AKI at Upcoming ADLM 2024 Clinical Lab Expo

GlobeNewswire • 29 Jul 2024 16:35

BioPorto to Debut FDA Approved ProNephro AKI at Upcoming ADLM 2024 Clinical Lab Expo

GlobeNewswire • 26 Jul 2024 17:15

Preliminary data suggests potential use beyond early AKI diagnosis for NGAL biomarker

GlobeNewswire • 17 Jul 2024 17:50

Results from Clinical Studies Highlight the Efficacy of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in Predicting Acute Kidney Injury

GlobeNewswire • 11 Jul 2024 17:15

Grant of Warrants

GlobeNewswire • 04 Jul 2024 17:54

BioPorto confirms market acceptance of NGAL products with US standing order.

GlobeNewswire • 01 Jul 2024 17:30

Managers’ transactions

GlobeNewswire • 24 Jun 2024 09:55

Changes of number of shares and votes in BioPorto A/S

GlobeNewswire • 24 Jun 2024 09:52

Private placement of 50,000,000 new shares oversubscribed - gross proceeds of DKK 81.4 million, corresponding to USD 11.7 million, to BioPorto A/S.

Private placement of 50,000,000 new shares oversubscribed - gross proceeds of DKK 81.

GlobeNewswire • 18 Jun 2024 08:14

BioPorto A/S initiates a private placement of 50,000,000 new shares at market price.

GlobeNewswire • 17 Jun 2024 19:04

BioPorto A/S Appoints Chief Financial Officer

GlobeNewswire • 30 May 2024 14:17

First Quarter 2024: Strong growth in US sales of The NGAL Test

GlobeNewswire • 08 May 2024 08:21

BioPorto A/S Appoints President and CEO of BioPorto Inc.

GlobeNewswire • 07 May 2024 13:10

BioPorto A/S to Host First Quarter 2024 Earnings Webcast and Investor Meeting

GlobeNewswire • 02 May 2024 13:53

Resolutions of Annual Geneal Meeting

GlobeNewswire • 30 Apr 2024 15:46

Grant of warrants

GlobeNewswire • 23 Apr 2024 19:20

BioPorto A/S Appoints Chief Legal Officer

GlobeNewswire • 10 Apr 2024 13:22

New Board Candidate for the upcoming Annual Geneal Meeting

GlobeNewswire • 05 Apr 2024 15:46

Notice convening the Annual General Meeting in BioPorto A/S

GlobeNewswire • 04 Apr 2024 11:07

Correction: BioPorto Announces Annual Results for 2023

GlobeNewswire • 04 Apr 2024 09:43

BioPorto Announces Annual Results for 2023

GlobeNewswire • 04 Apr 2024 08:29

BioPorto A/S to Host Annual Earnings Webcast

GlobeNewswire • 02 Apr 2024 10:47

BioPorto appoints Peter Mørch Eriksen as permanent Group Chief Executive Officer

GlobeNewswire • 02 Apr 2024 07:54

BioPorto announces preliminary results for 2023 and provides strategic update for the period 2024-2026

GlobeNewswire • 22 Feb 2024 07:31

Roche Diagnostics and BioPorto expand collaboration

GlobeNewswire • 20 Feb 2024 08:28

BioPorto A/S to host investor meetings on 22 February 2024

GlobeNewswire • 19 Feb 2024 07:41

BioPorto implements changes to the Executive Management.

GlobeNewswire • 09 Jan 2024 19:42

Managers’ transactions

GlobeNewswire • 09 Dec 2023 18:12

FDA Clears First Test to Identify Hospitalized Children at Risk for Acute Kidney Injury (AKI)

GlobeNewswire • 08 Dec 2023 17:02

BioPorto modtager FDA godkendelse i USA vedrørende NGAL Test til identificering af risiko for akut nyresvigt hos børn i alderen 3 måneder til 21 år

BioPorto modtager FDA godkendelse i USA vedrørende NGAL Test til identificering af risiko for akut nyresvigt hos børn i alderen 3 måneder t...

GlobeNewswire • 08 Dec 2023 08:13

BioPorto Receives FDA 510(k) Clearance for NGAL Test in the United States First Test to Aid in Assessing AKI Risk for Patients Aged 3 Months Through 21 Years

BioPorto Receives FDA 510(k) Clearance for NGAL Test in the United States First Test to Aid in Assessing AKI Risk for Patients Aged 3 Month...

GlobeNewswire • 07 Dec 2023 22:22

Resignation of Director

GlobeNewswire • 04 Dec 2023 20:00

BioPorto Announces Two Poster Presentations at ASN Kidney Week 2023 Conference

GlobeNewswire • 01 Nov 2023 17:40

BioPorto Announces Interim Results and Business Update For the Third Quarter and Nine Months of Fiscal 2023

GlobeNewswire • 01 Nov 2023 08:31

BioPorto provides interim Q3 results and revised 2023 Financial Guidance.

GlobeNewswire • 31 Oct 2023 15:17

BioPorto A/S to Host Third Quarter 2023 Earnings Webcast and Analyst Call

GlobeNewswire • 20 Oct 2023 18:14

Grant of Warrants

GlobeNewswire • 22 Sep 2023 18:59

BioPorto Initiates Search for new CFO as Neil Goldman Resigns

GlobeNewswire • 19 Sep 2023 15:16

BioPorto Provides Update on NGAL Test Regulatory Pathway

GlobeNewswire • 11 Sep 2023 08:30

BioPorto to Participate in Upcoming Investor Conferences

GlobeNewswire • 28 Aug 2023 17:32

BioPorto Announces Interim Results for the First Six Months of 2023

GlobeNewswire • 01 Aug 2023 08:48

BioPorto A/S to Host Second Quarter 2023 Earnings Webcast and Analyst Call

GlobeNewswire • 07 Jul 2023 14:55

BioPorto Announces Submission of Response to FDA Additional Information Letter

GlobeNewswire • 29 Jun 2023 08:11

Managers’ transactions

GlobeNewswire • 28 Jun 2023 15:50

BioPorto A/S announces completion of rights issue; total number of shares and voting rights

GlobeNewswire • 23 Jun 2023 07:49

BioPorto A/S announces results of rights issue

GlobeNewswire • 21 Jun 2023 13:52

BioPorto A/S to Webcast with HCA and Nordnet regarding the ongoing rights issue

GlobeNewswire • 09 Jun 2023 15:38

BioPorto A/S initiates a rights issue with pre-emptive rights for its existing shareholders and proceeds of up to approximately DKK 59.4 million with approximately DKK 16.6 million pre-subscribed pursuant to advance commitments

BioPorto A/S initiates a rights issue with pre-emptive rights for its existing shareholders and proceeds of up to approximately DKK 59.

GlobeNewswire • 30 May 2023 17:27

Increase in share capital following exercise of warrants – Notice of changes in share capital and voting rights pursuant to section 32 of the Danish Capital Markets Act

Increase in share capital following exercise of warrants – Notice of changes in share capital and voting rights pursuant to section 32 of th...

GlobeNewswire • 23 May 2023 20:02

BioPorto Announces Interim Results for the First Three Months of 2023

GlobeNewswire • 10 May 2023 08:20

BioPorto A/S to Host Quarterly Earnings Webcast and Analyst Call

GlobeNewswire • 03 May 2023 08:53

Resolutions of the General Meeting of BioPorto A/S

GlobeNewswire • 27 Apr 2023 16:14

Grant of Warrants

GlobeNewswire • 25 Apr 2023 22:12

Notice convening the Annual General Meeting in BioPorto A/S

GlobeNewswire • 05 Apr 2023 08:35

BioPorto Announces Annual Results for the Year ended December 31, 2022

GlobeNewswire • 30 Mar 2023 08:48

Pressmeddelanden från BioPorto

BioPorto Sponsors Conferences on Pediatric Critical Care with New NGAL Scientific Data Presented

US News & World Report Webinar “New Frontiers in Kidney Care” features NGAL biomarker

Grant of Warrants

ProNephro AKI™ (NGAL), early detection test for Acute Kidney Injury, now commercially available to US Labs through BioPorto’s collaboration with Roche Diagnostics.

BioPorto Interim Result for the Second Quarter of 2025 - Continued progress with full execution of strategic objectives and strong NGAL sales growth.

BioPorto A/S to host an investor webcast on the results for the first half of 2025

BioPorto attends the Association for Diagnostics & Laboratory Medicine meeting, where NGAL and Acute Kidney Injury will be a key focus among participants.

BioPorto attends the Association for Diagnostics & Laboratory Medicine meeting, where NGAL and Acute Kidney Injury will be a key focus among participants.

Initiation of commercialization of ProNephro AKI (NGAL) for diagnostic use in the US

Grant of Warrants

BioPorto A/S Announces the Appointment of a New CEO as Part of its Succession Planning Strategy

Continued progress on key strategic milestones in Q1 2025. Total revenue in line with expectations and guidance for 2025 maintained.

Grant of Warrants

BioPorto A/S to host first quarter 2025 earnings webcast for investors

BioPorto announces completion of an oversubscribed directed offering of 25 million new shares raising DKK 33.5 million

Managers’ transactions

BioPorto A/S raises DKK 33.5 million in new capital round - Change of number of shares and votes

Correction: Private placement of 25,000,000 new shares fully subscribed – gross proceeds of DKK 33.5 million, to BioPorto A/S

Private placement of 25,000,000 new shares fully subscribed – gross proceeds of DKK 33.5 million, to BioPorto A/S

BioPorto A/S initiates a private placement of up to 25,000,000 new shares at market price. The Board of Directors has received advance indications for the full offering which is expected to raise proceeds of DKK 33.5 million.

Resolutions of the Annual General Meeting

Updated biographies for board candidates at the upcoming Annual General Meeting

Notice convening the Annual General Meeting in BioPorto A/S

BioPorto announces the Annual Report for 2024

BioPorto announces guidance for 2025 and aspirations for 2026 towards 2029

BioPorto A/S announces Jens Due Olsen as a Board of Directors candidate intending to appoint Jens Due Olsen as Chair, along with updates on other candidates

Strengthening of Investor Focus – BioPorto enters Market Maker Agreement with Danske Bank & appoints New Head of Investor Relations

BioPorto A/S appoints new interim Chairman of the Board

BioPorto announces the publication of urinary NGAL reference ranges in healthy adult and pediatric individuals

Preliminary Financial Figures for the 2024 Fiscal Year

BioPorto commences process to appoint new Chair of the Board of Directors

BioPorto Announces Interim Results and Business Update for the Third Quarter and Nine Months of Fiscal 2024

BioPorto A/S to Host Third Quarter 2024 Earnings Webcast

BioPorto Sponsors Exhibits to Showcase Launch of ProNephro AKI in the U.S. and Ongoing Marketing of The NGAL Test to Clinicians at Major Healthcare Conferences

Grant of Warrants

First Patient In - BioPorto Initiates Patient Enrollment for US Study of ProNephro AKI (NGAL)™ for Adult Use at Massachusetts General Hospital

BioPorto Enters Global Distribution Partnership with Beckman Coulter for Acute Kidney Injury NGAL Tests

BioPorto Presenting FDA-cleared ProNephro AKI (NGAL) at ASN Kidney Week 2024 Conference

BioPorto is proud to have Nine of the top-ten best US Children’s hospitals as customers of NGAL

BioPorto A/S Announces Changes to the US Commercial Organization

BioPorto Announces Appointment of National Principal Investigator and Selection of CRO for Upcoming USA ICU Adult AKI Clinical Study

Første 6 måneder af 2024: Fortsat stærk vækst i salget af NGAL-tests i USA og fokuseret eksekvering af alle elementer i BioPortos strategi

BioPorto Announces Interim Results and Business Update for the Second Quarter and Six Months of Fiscal 2024

BioPorto A/S to Host Second Quarter 2024 Earnings Webcast & Investor Meeting

BioPorto Announces NIH-Funded Study to Explore the Ability of Renal Biomarkers in Predicting Severe AKI, Advancing Beyond NLP-based AI Algorithms

BioPorto to Debut FDA Approved ProNephro AKI at Upcoming ADLM 2024 Clinical Lab Expo

BioPorto to Debut FDA Approved ProNephro AKI at Upcoming ADLM 2024 Clinical Lab Expo

Preliminary data suggests potential use beyond early AKI diagnosis for NGAL biomarker

Results from Clinical Studies Highlight the Efficacy of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in Predicting Acute Kidney Injury

Grant of Warrants

BioPorto confirms market acceptance of NGAL products with US standing order.

Managers’ transactions

Changes of number of shares and votes in BioPorto A/S

Private placement of 50,000,000 new shares oversubscribed - gross proceeds of DKK 81.4 million, corresponding to USD 11.7 million, to BioPorto A/S.

BioPorto A/S initiates a private placement of 50,000,000 new shares at market price.

BioPorto A/S Appoints Chief Financial Officer

First Quarter 2024: Strong growth in US sales of The NGAL Test

BioPorto A/S Appoints President and CEO of BioPorto Inc.

BioPorto A/S to Host First Quarter 2024 Earnings Webcast and Investor Meeting

Resolutions of Annual Geneal Meeting

Grant of warrants

BioPorto A/S Appoints Chief Legal Officer

New Board Candidate for the upcoming Annual Geneal Meeting

Notice convening the Annual General Meeting in BioPorto A/S

Correction: BioPorto Announces Annual Results for 2023

BioPorto Announces Annual Results for 2023

BioPorto A/S to Host Annual Earnings Webcast

BioPorto appoints Peter Mørch Eriksen as permanent Group Chief Executive Officer

BioPorto announces preliminary results for 2023 and provides strategic update for the period 2024-2026

Roche Diagnostics and BioPorto expand collaboration

BioPorto A/S to host investor meetings on 22 February 2024

BioPorto implements changes to the Executive Management.

Managers’ transactions

FDA Clears First Test to Identify Hospitalized Children at Risk for Acute Kidney Injury (AKI)

BioPorto modtager FDA godkendelse i USA vedrørende NGAL Test til identificering af risiko for akut nyresvigt hos børn i alderen 3 måneder til 21 år

BioPorto Receives FDA 510(k) Clearance for NGAL Test in the United States First Test to Aid in Assessing AKI Risk for Patients Aged 3 Months Through 21 Years

Resignation of Director

BioPorto Announces Two Poster Presentations at ASN Kidney Week 2023 Conference

BioPorto Announces Interim Results and Business Update For the Third Quarter and Nine Months of Fiscal 2023